Independent Advisor Alliance Takes $791,000 Position in Indivior PLC $INDV

Independent Advisor Alliance bought a new position in shares of Indivior PLC (NASDAQ:INDV) in the fourth quarter, Holdings Channel reports. The firm bought 22,034 shares of the company’s stock, valued at approximately $791,000.

Several other hedge funds have also recently bought and sold shares of the business. Hennion & Walsh Asset Management Inc. increased its holdings in Indivior by 43.4% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 317,600 shares of the company’s stock valued at $11,395,000 after purchasing an additional 96,177 shares in the last quarter. Federated Hermes Inc. acquired a new position in shares of Indivior during the third quarter worth about $8,120,000. Aberdeen Group plc purchased a new stake in shares of Indivior in the third quarter worth about $3,875,000. Victory Capital Management Inc. purchased a new stake in shares of Indivior in the third quarter worth about $19,437,000. Finally, Claret Asset Management Corp grew its stake in shares of Indivior by 5.4% in the third quarter. Claret Asset Management Corp now owns 784,588 shares of the company’s stock valued at $18,916,000 after buying an additional 40,306 shares in the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on INDV. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 16th. Northland Securities set a $50.00 target price on shares of Indivior in a research report on Tuesday, January 20th. Finally, Weiss Ratings downgraded shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $39.33.

Insider Buying and Selling at Indivior

In related news, Director Stuart A. Kingsley purchased 940 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The stock was acquired at an average price of $31.86 per share, for a total transaction of $29,948.40. Following the completion of the purchase, the director owned 5,582 shares in the company, valued at approximately $177,842.52. This represents a 20.25% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.74% of the company’s stock.

Indivior Stock Performance

NASDAQ:INDV opened at $36.76 on Friday. The stock has a market cap of $4.48 billion, a price-to-earnings ratio of 18.85 and a beta of 0.90. Indivior PLC has a one year low of $11.04 and a one year high of $41.00. The business’s 50-day simple moving average is $32.93 and its 200 day simple moving average is $33.36.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%.The company had revenue of $317.00 million for the quarter. On average, equities research analysts predict that Indivior PLC will post 3.35 EPS for the current year.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.